Enhancement of anti-PD-L1 antibody plus anlotinib efficacy due to downregulation of PD-L1 in the micro-conduit endothelium within the tumor: a randomized double-blind trial

Authors

Cuicui Zhang

Published

May 29, 2024

Share your thoughts on this paper...

Supporters

Support the authors with ResearchCoin

Journal

Cancer Biology and Medicine

Topics

DOI

10.20892/j.issn.2095-3941.2023.0423

License

CC-BY-NC

Other Formats

PDF

Enhancement of anti-PD-L1 antibody plus anlotinib efficacy due to downregulation of PD-L1 in the micro-conduit endothelium within the tumor: a randomized double-blind trial

Authors

Cuicui Zhang

Published

May 29, 2024

Share your thoughts on this paper...

Supporters

Support the authors with ResearchCoin

Journal

Cancer Biology and Medicine

Topics

DOI

10.20892/j.issn.2095-3941.2023.0423

License

CC-BY-NC

Other Formats

PDF

Paper

Paper

Paper

Paper

Enhancement of anti-PD-L1 antibody plus anlotinib efficacy due to downregulation of PD-L1 in the micro-conduit endothelium within the tumor: a randomized double-blind trial

Supporters

Journal

Topics

DOI

License

Other Formats

Enhancement of anti-PD-L1 antibody plus anlotinib efficacy due to downregulation of PD-L1 in the micro-conduit endothelium within the tumor: a randomized double-blind trial

Supporters

Journal

Topics

DOI

License

Other Formats

Supporters

Journal

Topics

DOI

License

Other Formats